Updates in the Treatment of HR+ Breast Cancer : Episode 2
Opinion
Video
Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer
Author(s):
Expert breast oncologists examine adjuvant therapy approaches for early-stage hormone receptor-positive breast cancer, emphasizing the distinct treatment strategies and outcomes observed in pre- and post-menopausal patient populations.
- Treatment Approached for patients with early-stage HR+ breast cancer
- Dr. McCann:How do you use adjuvant therapy in patients with early-stage HR+ BC? How do treatment patterns and outcomes differ for pre- and post-menopausal women?
- Dr. McCann to ask Dr Hurvitz:How do studies like TAILORx and RxPONDERassist in making these decisions?
- Sparano Cancer Res 2023: (TAILORx): An update including 12-year event rates
- Kalinsky NEJM 2021 RxPonder; ASCO 2024 #505:RxPONDERguide treatment?
Related Videos
Related Content
